See more : Nihon Isk Co.,Ltd. (7986.T) Income Statement Analysis – Financial Results
Complete financial analysis of MaxCyte, Inc. (MXCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MaxCyte, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Bumrungrad Hospital Public Company Limited (BZ7A.F) Income Statement Analysis – Financial Results
- Western Digital Corporation (WDC.DE) Income Statement Analysis – Financial Results
- China Suntien Green Energy Corporation Limited (CSGEF) Income Statement Analysis – Financial Results
- Eat Well Investment Group Inc. (EWG.CN) Income Statement Analysis – Financial Results
- Tecsys Inc. (TCS.TO) Income Statement Analysis – Financial Results
MaxCyte, Inc. (MXCT)
About MaxCyte, Inc.
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41.29M | 44.26M | 33.89M | 26.17M | 21.62M | 16.67M | 13.99M | 12.27M | 9.29M | 7.16M | 6.81M | 5.06M |
| Cost of Revenue | 4.74M | 5.10M | 3.65M | 2.77M | 2.50M | 1.84M | 1.45M | 1.31M | 1.03M | 957.50K | 808.60K | 830.40K |
| Gross Profit | 36.55M | 39.16M | 30.25M | 23.40M | 19.12M | 14.83M | 12.53M | 10.96M | 8.26M | 6.21M | 6.00M | 4.23M |
| Gross Profit Ratio | 88.51% | 88.48% | 89.24% | 89.43% | 88.44% | 88.96% | 89.61% | 89.34% | 88.89% | 86.64% | 88.12% | 83.59% |
| Research & Development | 23.82M | 19.51M | 15.41M | 17.74M | 17.60M | 11.24M | 11.28M | 4.70M | 3.01M | 2.49M | 2.22M | 2.21M |
| General & Administrative | 30.07M | 25.83M | 18.68M | 8.39M | 6.09M | 5.28M | 4.52M | 4.20M | 2.67M | 2.47M | 2.21M | 2.02M |
| Selling & Marketing | 26.98M | 18.65M | 13.00M | 8.33M | 7.85M | 6.72M | 6.02M | 4.78M | 3.34M | 2.52M | 2.37M | 1.96M |
| SG&A | 57.04M | 44.48M | 31.68M | 16.71M | 13.94M | 12.01M | 10.54M | 8.99M | 6.01M | 4.99M | 4.59M | 3.98M |
| Other Expenses | 3.99M | 2.53M | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 15.70K | 20.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 84.85M | 66.52M | 48.44M | 34.46M | 31.54M | 23.25M | 21.82M | 13.69M | 9.02M | 7.48M | 6.80M | 6.19M |
| Cost & Expenses | 89.59M | 71.62M | 52.08M | 37.23M | 34.04M | 25.09M | 23.28M | 14.99M | 10.05M | 8.44M | 7.61M | 7.02M |
| Interest Income | 10.38M | 3.92M | 150.80K | 65.90K | 206.10K | 170.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.80K |
| Interest Expense | 0.00 | 126.90K | 1.04M | 825.60K | 681.10K | 614.60K | 625.30K | 637.80K | 704.40K | 561.30K | 153.50K | 61.70K |
| Depreciation & Amortization | 4.17M | 2.70M | 1.42M | 1.05M | 613.50K | 344.00K | 142.90K | 105.70K | 93.30K | 92.00K | 116.40K | 115.20K |
| EBITDA | -44.13M | -20.87M | -16.76M | -9.94M | -11.60M | -7.91M | -9.15M | -2.60M | -647.80K | -1.18M | -688.30K | -1.81M |
| EBITDA Ratio | -106.88% | -46.87% | -49.02% | -38.00% | -53.65% | -47.46% | -65.42% | -21.21% | -6.97% | -16.52% | -10.11% | -35.80% |
| Operating Income | -48.30M | -27.36M | -18.19M | -11.06M | -12.42M | -8.42M | -9.29M | -2.72M | -761.10K | -1.28M | -804.70K | -1.96M |
| Operating Income Ratio | -116.98% | -61.82% | -53.66% | -42.25% | -57.44% | -50.55% | -66.44% | -22.20% | -8.19% | -17.81% | -11.83% | -38.79% |
| Total Other Income/Expenses | 10.38M | 3.79M | -893.60K | -759.70K | -475.00K | -444.30K | -625.30K | -622.10K | -684.40K | -561.30K | -153.50K | -25.90K |
| Income Before Tax | -37.92M | -23.57M | -19.08M | -11.82M | -12.90M | -8.87M | -9.92M | -3.35M | -1.45M | -1.84M | -958.20K | -1.99M |
| Income Before Tax Ratio | -91.85% | -53.25% | -56.30% | -45.15% | -59.64% | -53.21% | -70.91% | -27.27% | -15.56% | -25.64% | -14.08% | -39.30% |
| Income Tax Expense | 0.00 | -3.79M | 1.04M | 825.60K | 681.10K | 170.30K | 0.00 | 653.50K | 724.40K | 0.00 | 0.00 | 35.80K |
| Net Income | -37.92M | -19.78M | -20.13M | -12.64M | -13.58M | -8.87M | -9.92M | -3.35M | -1.45M | -1.84M | -958.20K | -1.99M |
| Net Income Ratio | -91.85% | -44.69% | -59.38% | -48.31% | -62.79% | -53.21% | -70.91% | -27.27% | -15.56% | -25.64% | -14.08% | -39.30% |
| EPS | -0.37 | -0.19 | -0.22 | -0.18 | -0.24 | -0.17 | -0.20 | -0.10 | -0.03 | -0.04 | -0.02 | -0.05 |
| EPS Diluted | -0.37 | -0.19 | -0.22 | -0.18 | -0.24 | -0.17 | -0.20 | -0.10 | -0.03 | -0.04 | -0.02 | -0.05 |
| Weighted Avg Shares Out | 103.27M | 101.70M | 90.62M | 69.46M | 56.40M | 51.18M | 48.64M | 33.52M | 43.47M | 43.47M | 43.47M | 43.47M |
| Weighted Avg Shares Out (Dil) | 103.27M | 101.70M | 90.62M | 69.46M | 56.40M | 51.18M | 48.64M | 33.52M | 43.47M | 43.47M | 43.47M | 43.47M |
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects Since 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects
MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.11 per share a year ago.
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for...
MaxCyte to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company management will participate...
MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock?
MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
MaxCyte Appoints Cynthia Collins to its Board of Directors
ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced...
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced...
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced...
Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up
MaxCyte, Inc.'s stock performance has been disappointing since its 2021 IPO, despite positive business developments and a 34% revenue growth. The company faces high capital requirements for modest revenue gains, but has a substantial cash reserve to sustain operations. FDA...
Source: https://incomestatements.info
Category: Stock Reports